Bartomeu Massutí
About
Bartomeu Massutí is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Molecular Biology.
According to data from OpenAlex, Bartomeu Massutí has authored 199 papers receiving a total of 6.5k indexed citations (citations by other indexed papers that have themselves been cited), including 138 papers in Pulmonary and Respiratory Medicine, 138 papers in Oncology and 41 papers in Molecular Biology. Recurrent topics in Bartomeu Massutí's work include Lung Cancer Treatments and Mutations (104 papers), Colorectal Cancer Treatments and Studies (56 papers) and Lung Cancer Diagnosis and Treatment (49 papers). Bartomeu Massutí is often cited by papers focused on Lung Cancer Treatments and Mutations (104 papers), Colorectal Cancer Treatments and Studies (56 papers) and Lung Cancer Diagnosis and Treatment (49 papers). Bartomeu Massutí collaborates with scholars based in Spain, United States and France. Bartomeu Massutí's co-authors include Rafael Rosell, Manuel Cobo, Carlos Camps, Vicente Alberola, Dolores Isla, José Javier Sánchez, Enriqueta Felip, Miquel Tarón, Alfredo Carrato and Teresa Morán and has published in prestigious journals such as Journal of Clinical Oncology, PLoS ONE and Cancer.
In The Last Decade
Bartomeu Massutí
189 papers receiving 6.4k citations
Hit Papers
Peers — A (Enhanced Table)
Peers by citation overlap · career bar shows stage (early→late) cites · hero ref
| Name | h | Career | Trend | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Bartomeu Massutí Spain | 39 | 4.6k | 3.6k | 1.5k | 1.1k | 967 | 199 | 6.5k | ||
| Junming Zhu China | 11 | 4.1k 0.9× | 4.3k 1.2× | 1.8k 1.2× | 879 0.8× | 941 1.0× | 29 | 7.3k | ||
| Vladimir Moiseyenko Russia | 33 | 5.6k 1.2× | 4.1k 1.2× | 1.0k 0.7× | 1.3k 1.2× | 1.8k 1.8× | 142 | 8.1k | ||
| P. Koralewski Poland | 23 | 4.5k 1.0× | 3.5k 1.0× | 2.1k 1.4× | 1.7k 1.6× | 926 1.0× | 58 | 7.1k | ||
| Ihor Vynnychenko Ukraine | 21 | 4.6k 1.0× | 4.3k 1.2× | 1.4k 0.9× | 901 0.8× | 1.4k 1.4× | 57 | 7.0k | ||
| Scott A. Laurie Canada | 36 | 4.3k 0.9× | 3.3k 0.9× | 1.2k 0.8× | 685 0.6× | 1.2k 1.3× | 163 | 6.3k | ||
| Hidetoshi Hayashi Japan | 36 | 3.7k 0.8× | 2.8k 0.8× | 1.4k 0.9× | 705 0.6× | 400 0.4× | 248 | 5.2k | ||
| David M. Jackman United States | 38 | 4.9k 1.1× | 5.6k 1.6× | 2.0k 1.3× | 1.7k 1.5× | 388 0.4× | 87 | 7.6k | ||
| Roberto Iacovelli Italy | 34 | 2.1k 0.5× | 2.6k 0.7× | 1.5k 1.0× | 1.2k 1.1× | 712 0.7× | 224 | 4.6k | ||
| Rafael Rosell Spain | 43 | 4.3k 0.9× | 4.8k 1.3× | 3.2k 2.1× | 1.7k 1.6× | 737 0.8× | 144 | 8.0k | ||
| Salah‐Eddin Al‐Batran Germany | 39 | 3.2k 0.7× | 3.3k 0.9× | 801 0.5× | 532 0.5× | 1.9k 1.9× | 214 | 5.6k |
Countries citing papers authored by Bartomeu Massutí
Since
Specialization
Citations
This map shows the geographic impact of Bartomeu Massutí's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Bartomeu Massutí with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Bartomeu Massutí more than expected).
Fields of papers citing papers by Bartomeu Massutí
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Bartomeu Massutí. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Bartomeu Massutí. The network helps show where Bartomeu Massutí may publish in the future.
Co-authorship network of co-authors of Bartomeu Massutí
This figure shows the co-authorship network connecting the top 25 collaborators of Bartomeu Massutí. A scholar is included among the top collaborators of Bartomeu Massutí based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Bartomeu Massutí. Bartomeu Massutí is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Nadal, Ernest, Bartomeu Massutí, Aránzazu García‐Grande, et al.. (2025). Peripheral memory B cell population maintenance and long-term survival after perioperative chemoimmunotherapy in NSCLC (NADIM trial). OncoImmunology. 14(1). 2513109–2513109.
2.
Nadal, Ernest, Paloma Martín-Martorell, José Carlos Benítez, et al.. (2025). Efficacy and safety of bintrafusp alfa evaluated in a phase II single-arm clinical trial in previously treated advanced pleural mesothelioma. Lung Cancer. 203. 108545–108545.
3.
Leighl, Natasha B., Hiroaki Akamatsu, Ying Cheng, et al.. (2024). Subcutaneous amivantamab vs intravenous amivantamab, both in combination with lazertinib, in refractory EGFR-mutated, advanced non-small cell lung cancer (NSCLC): Primary results, including overall survival (OS), from the global, phase 3, randomized controlled PALOMA-3 trial.. Journal of Clinical Oncology. 42(17_suppl). LBA8505–LBA8505.
4.
Postel‐Vinay, Sophie, Matthieu Texier, Mihaela Aldea, et al.. (2023). Olaparib maintenance versus placebo in platinum-sensitive non-small cell lung cancer: the Phase 2 randomized PIPSeN trial. British Journal of Cancer. 130(3). 417–424.
5.
Torrente, María, Luca Costabello, Virginia Calvo, et al.. (2023). Machine Learning–Assisted Recurrence Prediction for Patients With Early-Stage Non–Small-Cell Lung Cancer. JCO Clinical Cancer Informatics. 7(7). e2200062–e2200062.
6.
Calvo, Virginia, Carlos Camps, Enric Carcereny, et al.. (2023). Difficulties on the access to innovative targeted therapies for lung cancer in Spain. Clinical & Translational Oncology. 26(3). 597–612.
7.
Cho, Byoung Chul, Delvys Rodríguez‐Abreu, Maen Hussein, et al.. (2022). Tiragolumab plus atezolizumab versus placebo plus atezolizumab as a first-line treatment for PD-L1-selected non-small-cell lung cancer (CITYSCAPE): primary and follow-up analyses of a randomised, double-blind, phase 2 study. The Lancet Oncology. 23(6). 781–792.
8.
Conde, Elisa, Julie Earl, José Carlos Martínez Ávila, et al.. (2021). Biomarkers Associated with Regorafenib First-Line Treatment Benefits in Metastatic Colorectal Cancer Patients: REFRAME Molecular Study. Cancers. 13(7). 1710–1710.
9.
Campos, Begoña, et al.. (2020). Prognostic factors for survival in patients with metastatic lung adenocarcinoma: An analysis of the SEER database. Thoracic Cancer. 11(11). 3357–3364.
10.
Provencio, Mariano, Enric Carcereny, Delvys Rodríguez‐Abreu, et al.. (2019). Lung cancer in Spain: information from the Thoracic Tumors Registry (TTR study). Translational Lung Cancer Research. 8(4). 461–475.
11.
Costa, Carlota, Miguel Angel Molina, Ana Drozdowskyj, et al.. (2014). The Impact of EGFR T790M Mutations and BIM mRNA Expression on Outcome in Patients with EGFR -Mutant NSCLC Treated with Erlotinib or Chemotherapy in the Randomized Phase III EURTAC Trial. Clinical Cancer Research. 20(7). 2001–2010.
12.
Molina‐Vila, Miguel Ángel, Jordi Bertrán-Alamillo, Amaya Gascó, et al.. (2014). Nondisruptive p53 Mutations Are Associated with Shorter Survival in Patients with Advanced Non–Small Cell Lung Cancer. Clinical Cancer Research. 20(17). 4647–4659.
13.
Cutsem, Eric Van, C. Boni, Josep Tabernero, et al.. (2014). Docetaxel plus oxaliplatin with or without fluorouracil or capecitabine in metastatic or locally recurrent gastric cancer: a randomized phase II study. Annals of Oncology. 26(1). 149–156.
14.
Sastre, Javier, Marta Vidaurreta, Fernando Rivera, et al.. (2013). Prognostic Value of the Combination of Circulating Tumor Cells Plus KRAS in Patients With Metastatic Colorectal Cancer Treated With Chemotherapy Plus Bevacizumab. Clinical Colorectal Cancer. 12(4). 280–286.
15.
Rosell, Rafael, A. Vergnenègre, Baorui Liu, et al.. (2010). Biomarkers in lung oncology. Pulmonary Pharmacology & Therapeutics. 23(6). 508–514.
16.
Skrzypski, Marcin, Ewa Jassem, Miquel Tarón, et al.. (2008). Three-Gene Expression Signature Predicts Survival in Early-Stage Squamous Cell Carcinoma of the Lung. Clinical Cancer Research. 14(15). 4794–4799.
17.
García, A., R. Pérez-Carrión, Javier de Castro, et al.. (2007). P3-082: Erlotinib as third and successive line of treatment in advanced or metastatic non-small cell lung cancer patients. Journal of Thoracic Oncology. 2(8). S713–S714.
18.
Garrido, Pilar, Bartomeu Massutí, Jordi Andreu, et al.. (2007). C3-02: Randomized phase II trial using concomitant chemoradiation plus induction (I) or consolidation (C) chemotherapy (CT) for unresectable stage III non-small cell lung cancer (NSCLC) patients (p). Mature results of the SLCG 0008 study. Journal of Thoracic Oncology. 2(8). S365–S365.
19.
Martín, Conchita, et al.. (1999). Bilateral lymphocytic alveolitis: a common reaction after unilateral thoracic irradiation. European Respiratory Journal. 13(4). 727–727.
20.
Carrato, Alfredo, Rafael Rosell, Carlos Camps, et al.. (1997). Modified weekly regimen with vinorelbine as a single agent in unresectable non-small cell lung cancer. Lung Cancer. 17(2-3). 261–269.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Junming Zhu Breakdown of academic impact, for papers by Vladimir Moiseyenko Breakdown of academic impact, for papers by P. Koralewski Breakdown of academic impact, for papers by Ihor Vynnychenko Breakdown of academic impact, for papers by Scott A. Laurie Breakdown of academic impact, for papers by Hidetoshi Hayashi Breakdown of academic impact, for papers by David M. Jackman Breakdown of academic impact, for papers by Roberto Iacovelli Breakdown of academic impact, for papers by Rafael Rosell Breakdown of academic impact, for papers by Salah‐Eddin Al‐Batran